使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good morning, ladies and gentlemen, and welcome to Baxter International's Second Quarter 2019 Earnings Conference Call. (Operator Instructions) As a reminder, this call is being recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission.
各位女士、先生,早安,歡迎參加百特國際(Baxter International)2019 年第二季財報電話會議。(接線員指示)提醒各位,本次電話會議由百特錄音並受著作權保護。未經百特許可,不得錄音或轉播。
If you have any objections, please disconnect at this time.
如有任何異議,請於此時中斷連線。
I would now like to turn the call over to Ms. Clare Trachtman, Vice President, Investor Relations at Baxter International. Ms. Trachtman, you may begin.
現在我想把電話交給百特國際投資人關係副總裁 Clare Trachtman 女士。Trachtman 女士,請開始。
Clare Trachtman - VP of IR
Clare Trachtman - VP of IR
Thanks, Judith. Good morning, and welcome to our second quarter 2019 earnings conference call. Joining me today are Joe Almeida, Baxter's Chairman and Chief Executive Officer; and Jay Saccaro, Baxter's Chief Financial Officer.
謝謝你,Judith。各位早安,歡迎參加我們 2019 年第二季財報電話會議。今天與我一同出席的有百特董事長兼執行長 Joe Almeida,以及百特財務長 Jay Saccaro。
On the call this morning, we will be discussing Baxter's second quarter 2019 financial results and our updated financial outlook for full year 2019. A supplemental presentation to complement this morning's discussion could be accessed on our website. This presentation, along with related non-GAAP reconciliations, could be accessed on Baxter's external website in the Investor section under Events and News.
今天上午的電話會議中,我們將討論百特 2019 年第二季財務結果,以及我們更新後的 2019 年全年財務展望。可至我們網站取得補充簡報,以配合今天上午的討論。該簡報及相關的非 GAAP 調節表,可於百特對外網站「投資人」專區的「活動與新聞」項下取得。
With that, let me start our prepared remarks by reminding everyone that this presentation, including comments regarding our financial outlook, new product development, business development and regulatory matters contains forward-looking statements that involve risks and uncertainties and, of course, our actual results could differ materially from our current expectations. Please refer to today's press release and our SEC filings for more details concerning factors that could cause actual results to differ materially.
接下來,我先在預先準備的發言中提醒各位:本簡報(包括關於我們財務展望、新產品開發、業務發展及法規事項的評論)包含前瞻性陳述,涉及風險與不確定性,當然,我們的實際結果可能與目前預期有重大差異。關於可能導致實際結果與預期有重大差異的因素,請參閱今日新聞稿及我們向 SEC 提交的文件以取得更多資訊。
In addition, on today's call, non-GAAP financial measures will be used to help investors understand Baxter's ongoing business performance. A reconciliation of the non-GAAP financial measures being discussed today to the comparable GAAP financial measures is included in our earnings release issued this morning and is available on our website.
此外,在今天的電話會議中,我們將使用非 GAAP 財務衡量指標,以協助投資人了解百特持續經營的業務表現。今日所討論之非 GAAP 財務衡量指標與可比較之 GAAP 財務衡量指標的調節表,已包含於我們今早發布的財報新聞稿中,並可於我們網站取得。
On the call this morning, we will be discussing operational sales growth, which adjusts for the impact of foreign exchange and generic competition for cyclophosphamide in the U.S.
今天上午的電話會議中,我們將討論營運銷售成長(operational sales growth),其已調整外匯影響,以及美國市場環磷醯胺(cyclophosphamide)面臨學名藥競爭的影響。
Now I'd like to turn the call over to Joe.
現在我想把電話交給 Joe。
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Good morning, and thank you for joining us. We're pleased to share our second quarter results with you today and to discuss our updated expectations for 2019.
各位早安,感謝各位加入我們。我們很高興今天與各位分享第二季的業績,並討論我們對 2019 年更新後的預期。
I will begin with a quick review of our performance in the quarter, and Jay will then provide more detail on the financials. We'll wrap up with Q&A.
我將先快速回顧本季表現,接著 Jay 會提供更詳細的財務說明。最後我們將進行問答。
Baxter maintained its positive trajectory in the second quarter of 2019, delivering sales growth of 4% on both a constant currency and operational basis.
百特在 2019 年第二季維持正向成長軌跡,以固定匯率與營運基礎計算,銷售成長皆為 4%。
On the bottom line, adjusted earnings per share were $0.89, exceeding our expectations and up 16% year-over-year. Growth in the quarter was driven by top line sales performance, operational efficiency initiatives, a lower tax rate and a reduced share count. All 6 of our Global Business Units contributed positively to constant currency sales growth, powered, in part, by our revitalized innovation efforts.
在獲利方面,調整後每股盈餘為 0.89 美元,優於我們的預期,且年增 16%。本季成長主要由營收表現、營運效率提升措施、較低的稅率以及股數減少所帶動。我們 6 個全球事業部門皆對固定匯率銷售成長做出正面貢獻,其中部分動能來自我們重新振興的創新投入。
On a constant currency basis, global growth in the Renal Care continues to be driven by increasing patient volumes for our peritoneal dialysis products. As expected, results in the quarter were negatively impacted due to the strategic exit of the U.S. in-center hemodialysis bloodlines business. Performance was also impacted by a recall and certain manufacturing challenges at one of our facilities that produces Revaclear dialyzers used for hemodialysis.
以固定匯率計算,腎臟照護(Renal Care)在全球的成長持續由腹膜透析產品的病患量增加所驅動。如預期,本季結果因策略性退出美國院內血液透析血路(in-center hemodialysis bloodlines)業務而受到負面影響。此外,我們一處生產用於血液透析之 Revaclear 透析器的廠房,因召回事件及部分製造挑戰而影響表現。
This is creating a temporary supply constraint, as we have been selectively slowing down production lines at this facility to address this situation. However, Revaclear production is now ramping up, and we expect to return to healthier inventory levels over the next few months. We do expect to incur incremental costs in the second half of the year, as we work to enhance our production capabilities at this facility.
這造成短期供應受限,因為我們已在該廠選擇性放慢部分產線,以處理此情況。不過,Revaclear 的生產目前正逐步提升,我們預期未來幾個月可回到較健康的庫存水位。在我們致力提升該廠生產能力的同時,預期今年下半年將產生額外成本。
I also wanted to take a moment to discuss the recent advance in American Kidney Health Initiative announced by the White House earlier this month. As proposed, it would have a transformative impact on the treatment of end-stage renal disease, or ESRD, in the U.S. This is part of an emerging trend taking shape in worldwide, as payers, clinicians and patients increasingly embrace home PD as a frontline ESRD treatment option based on key economic, therapeutic and lifestyle benefits.
我也想花點時間談談白宮於本月稍早宣布的「美國腎臟健康倡議」(American Kidney Health Initiative)近期進展。依其提案,該倡議將對美國末期腎臟病(end-stage renal disease,ESRD)的治療帶來變革性影響。這也是全球正在成形的一股新趨勢:付款方、臨床醫師與病患基於關鍵的經濟、治療與生活型態效益,愈來愈多將居家腹膜透析(home PD)視為 ESRD 的第一線治療選項。
Baxter is the pioneer and global market leader in home PD and we fully support this initiative to broaden the adoption of home dialysis across the United States. As noted in our release this morning, we anticipate capital investments of $500 million to significantly increase our production capacity and meet new patient needs in line with proposed CMS models.
百特是居家腹膜透析的先驅與全球市場領導者,我們全力支持此倡議,以擴大居家透析在全美的採用。如同我們今早新聞稿所述,我們預期將投入 5 億美元資本支出,以大幅提升產能,並依照擬議的 CMS 模式滿足新增病患需求。
These investments will be scaled to align with the patient and market dynamics across the innovation curve. Increased demand would in turn help accelerate Renal Care growth and contribute positively to Baxter's previously communicated financial estimates.
這些投資將依照創新曲線上不同階段的病患與市場動態進行調整與配置。需求增加將有助於加速腎臟照護業務成長,並對百特先前所溝通的財務估計帶來正面貢獻。
We are working to model the anticipated impacts and expect to be in a better position to provide additional information about what this initiative means for Baxter, once the rule is potentially finalized later this year.
我們正著手建立預期影響的模型,並預期在今年稍晚該規則可能定案後,能更有條件提供更多關於此倡議對百特意涵的資訊。
Moving on our Medication Delivery business returned to solid, constant currency growth globally. We're now emerging from a challenging performance comparison due to spike in demand for large volume IV solutions in the first half of 2018. Growth this quarter benefited from the continued uptake of our new infusion pumps, Spectrum IQ in the U.S. and Evo IQ in selected international markets and related disposables. Increased sales for Mini-Bag Plus in the U.S. and large volume IV solutions internationally also contributed to the growth in the quarter.
接著談到我們的藥物輸注(Medication Delivery)業務,全球以固定匯率計算已回到穩健成長。我們目前正走出一段具挑戰性的比較基期,該基期源自 2018 年上半年大型容量靜脈輸液(large volume IV solutions)需求激增。本季成長受惠於我們新型輸注幫浦在美國的 Spectrum IQ,以及在部分國際市場的 Evo IQ 及其相關耗材持續導入。此外,美國 Mini-Bag Plus 銷售增加,以及國際市場大型容量靜脈輸液的銷售成長,也共同推動本季成長。
Mid-single-digit constant currency growth in our Pharmaceuticals business was driven by increased demand for Baxter hospital pharmacy compounding services. The contribution from recent launches of injectable pharmaceuticals such as dexmed and the Baxter Ahmedabad business. This strength helped offset the expected impact of generic competition in U.S. for BREVIBLOC and cyclophosphamide.
我們製藥(Pharmaceuticals)業務以固定匯率計算呈現中個位數成長,主要由百特醫院藥局調配(compounding)服務需求增加所帶動。近期推出的注射用藥(如 dexmed)以及百特 Ahmedabad 業務亦有所貢獻。這些強勁表現有助於抵銷美國市場 BREVIBLOC 與環磷醯胺面臨學名藥競爭的預期影響。
The Pharmaceuticals business remains a key growth driver for the company. And we'll continue to benefit from new product launches, including the recent approval of Myxredlin, the first and only ready-to-use insulin for IV infusion in a hospital or acute care setting.
製藥業務仍是公司關鍵的成長動能。我們也將持續受惠於新產品上市,包括近期核准的 Myxredlin——這是首款且目前唯一可即用(ready-to-use)的靜脈輸注胰島素,適用於醫院或急性照護環境。
Baxter's Clinical Nutrition business delivered low single-digit sales growth globally on a constant currency basis. We're continuing to rebuild momentum here, supported, in part, by the launch of new products, including OLIMEL N12, higher protein formulation and FINOMEL, our novel fish oil-based triple-chamber container. We're also positioning for a U.S. launch of Clinolipid, Baxter's proprietary olive oil-based lipid emulsion later this year.
百特臨床營養(Clinical Nutrition)業務以固定匯率計算,全球銷售呈現低個位數成長。我們正持續重建此業務動能,部分受惠於新產品上市,包括 OLIMEL N12(較高蛋白配方)以及 FINOMEL(我們創新的魚油基三腔袋容器)。我們也正為今年稍晚在美國推出 Clinolipid 做準備;Clinolipid 為百特專有的橄欖油基脂肪乳劑。
Advanced Surgery delivered high teens growth at constant currency rates. Performance in the quarter benefited from competitive supply constraints, which resulted in incremental demand for both FLOSEAL and RECOTHROM.
先進外科(Advanced Surgery)以固定匯率計算呈現高十位數成長。本季表現受惠於競爭對手供應受限,使 FLOSEAL 與 RECOTHROM 兩項產品出現額外需求。
Finally, Acute Therapies posted high single-digit, constant currency growth, fueled, in part, by the ongoing rollout of our PrisMAX next-generation technology for CRRT and therapeutic plasma exchange. PrisMAX can be found in the intensive care units in more than 20 countries across Europe and Asia-Pacific. There are plans to bring additional markets onboard through 2020.
最後,急性治療(Acute Therapies)在固定匯率下實現高個位數成長,部分受惠於我們PrisMAX新一代技術在CRRT與治療性血漿置換領域的持續推廣。PrisMAX已進入歐洲與亞太地區超過20個國家的加護病房。我們計畫在2020年前將更多市場納入。
As all these highlights reflect, we are continuing to see Baxter's renewed emphasis on innovation, gaining traction and delivering results across our businesses. There is a great promise and potential ahead, fueled by our research and development pipeline, strong balance sheet and emerging opportunities. Most importantly, our employees, who are inspired and empowered by our mission to save and sustain lives. Our transformation is on track, and we remain absolutely focused on delivering sustainable top quartile performance and service our patients, shareholders and the rest of our broad stakeholder base.
正如這些亮點所反映的,我們持續看到百特(Baxter)重新強調創新,正逐步取得動能,並在各項業務中帶來成果。在我們的研發產品線、強健的資產負債表以及新興機會的推動下,前方充滿可期的承諾與潛力。最重要的是,我們的員工受到「拯救並延續生命」使命的啟發並被賦權。我們的轉型正按計畫推進,我們仍將絕對專注於提供可持續的前四分位績效,並服務我們的病患、股東以及廣泛的利害關係人。
Now I'll pass it on to Jay for a closer look at our financials and outlook.
接下來我把時間交給Jay,請他更深入說明我們的財務表現與展望。
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
Thanks, Joe, and good morning, everyone. As Joe mentioned, our second quarter results reflect solid constant currency growth across each of our 6 business units and further enforce confidence in our full year outlook. I'll start by discussing our second quarter results before providing our updated financial outlook for 2019.
謝謝你,Joe,各位早安。如Joe所提到,我們第二季的結果反映出在6個事業單位皆有穩健的固定匯率成長,並進一步強化我們對全年展望的信心。我將先討論第二季業績,接著提供我們更新後的2019年財務展望。
Beginning with the second quarter, global sales of $2.8 billion were flat on a reported basis and increased 4% on both the constant currency and operational basis, reflecting strength across our portfolio.
先從第二季開始,全球銷售額為28億美元,按報告基礎持平;按固定匯率與營運基礎皆成長4%,反映我們產品組合的整體強勁表現。
On bottom line, adjusted earnings increased 16% to $0.89 per diluted share. This exceeded our guidance of $0.80 to $0.82 per diluted share driven by top line performance, ongoing operational efficiencies and a lower tax rate.
在獲利端,調整後盈餘成長16%,至每股稀釋後0.89美元。此結果高於我們每股稀釋後0.80至0.82美元的指引,主要受營收表現、持續的營運效率提升以及較低的稅率所帶動。
Now I'll walk you through performance by our geographic segments and global businesses. Note, for this quarter, constant currency sales growth is equal to operational sales growth for all businesses and region segments except for our Pharmaceuticals business and the Americas region, for which we'll provide operational growth in addition to constant currency growth.
接下來我將帶各位檢視按地理區隔與全球業務的表現。請注意,本季除製藥業務與美洲區外,所有業務與區域的固定匯率銷售成長等同於營運銷售成長;對於製藥業務與美洲區,我們將在提供固定匯率成長之外,同時提供營運成長。
Starting first with sales growth for our 3 geographic segments. Sales in the Americas grew 1% on a constant currency basis and 2% operationally. Sales in EMEA grew 6% on a constant currency basis, and sales in our Asia-Pacific region advanced 9% on a constant currency basis.
先看三個地理區隔的銷售成長。美洲區銷售按固定匯率成長1%,按營運基礎成長2%。EMEA(歐洲、中東與非洲)按固定匯率成長6%,亞太地區按固定匯率成長9%。
Moving to performance by global businesses. Global sales for Renal Care were $910 million, advancing 3% on a constant currency basis. Performance in the quarter was driven by high single-digit growth in PD therapies globally. Partially offsetting this growth was the lower sales of select in-center HD products, including the bloodlines business exited earlier this year, which negatively impacted sales in the quarter by approximately $14 million.
接著看各全球業務的表現。腎臟照護(Renal Care)全球銷售額為9.10億美元,按固定匯率成長3%。本季表現主要由全球腹膜透析(PD)治療的高個位數成長所帶動。部分抵銷該成長的是部分院內血液透析(HD)產品銷售下滑,包括今年稍早退出的血路(bloodlines)業務,約使本季銷售減少1,400萬美元。
Renal Care sales growth in the quarter was also impacted by the recall and temporary supply constraints associated with the Revaclear dialyzer. The impact was less than $10 million in the quarter.
本季腎臟照護的銷售成長亦受到Revaclear透析器召回及相關暫時性供應限制的影響。本季影響金額低於1,000萬美元。
Sales in Medication Delivery of $689 million grew 4% on a constant currency basis, representing a return to solid and balanced growth in both the U.S. and internationally.
用藥輸送(Medication Delivery)銷售額為6.89億美元,按固定匯率成長4%,代表美國與國際市場皆回到穩健且均衡的成長。
Performance in the quarter benefited from strength in infusion systems following the launch of Spectrum IQ and Evo IQ, international growth of large volume IV solutions, particularly in Latin America and the continued momentum for Mini-Bag Plus.
本季表現受惠於輸注系統的強勁需求(在Spectrum IQ與Evo IQ上市後),大容量靜脈注射(IV)溶液的國際成長(尤其在拉丁美洲),以及Mini-Bag Plus持續的成長動能。
We are pleased with the sequential and year-over-year growth acceleration in our Medication Delivery business.
我們對用藥輸送業務在環比與同比的成長加速感到滿意。
Pharmaceutical sales were $539 million, increasing 4% constant currency and 7% operationally. Strong international sales contributed to performance in the quarter, driven by the increased demand for our hospital pharmacy compounding services, generic injectables, including Baxter Ahmedabad and anesthesia products. This growth was partially offset by declines in our U.S. business, which reflected approximately $40 million of lower U.S. sales of BREVIBLOC and cyclo as compared to the prior year period.
製藥(Pharmaceutical)銷售額為5.39億美元,按固定匯率成長4%,按營運基礎成長7%。本季表現受強勁的國際銷售貢獻,主要由醫院藥局調配服務需求增加、學名針劑(包括Baxter Ahmedabad)以及麻醉產品所帶動。此成長部分被美國業務下滑所抵銷;與去年同期相比,美國BREVIBLOC與cyclo銷售較低,約減少4,000萬美元。
Sales in the U.S. were also impacted by lower sales of anesthesia and critical care products in the quarter.
本季美國銷售亦受到麻醉與重症照護產品銷售下滑的影響。
Moving to Nutrition. Total sales were $215 million, up 2% on a constant currency basis and reflect sequential improvement in both the U.S. and internationally. We expect sales to continue to ramp throughout 2019, as we work to rebuild our U.S. business and capitalize on new product launches.
接著看營養(Nutrition)。總銷售額為2.15億美元,按固定匯率成長2%,並反映美國與國際市場皆有環比改善。隨著我們致力於重建美國業務並把握新產品上市機會,我們預期2019年銷售將持續逐步提升。
Sales of $232 million in Advanced Surgery increased 17% on a constant currency basis. Strong global growth benefited from our ability to address competitive supply constraints in the hemostat market in the U.S. These supply dynamics contributed approximately 12 percentage points to growth in the quarter.
先進外科(Advanced Surgery)銷售額為2.32億美元,按固定匯率成長17%。強勁的全球成長受惠於我們在美國止血劑市場能夠因應競品供應受限。這些供應動態約為本季成長貢獻12個百分點。
Sales in our Acute Therapies business were $133 million, representing growth of 8% on a constant currency basis. Growth in this business is now normalized after a difficult year-over-year comparison in the first quarter, and we continue to see growth globally driven by new product launches and demand for Baxter's CRRT therapies.
急性治療(Acute Therapies)業務銷售額為1.33億美元,按固定匯率成長8%。在第一季面臨艱難的同比比較後,該業務成長現已回歸常態;我們持續看到在新產品上市以及市場對百特CRRT治療需求帶動下的全球成長。
Finally, sales in our other category, which primarily includes our contract manufacturing services, were $122 million, a decrease of 9% on a constant currency basis, reflecting a challenging comparison to the prior year period.
最後,其他類別(主要包含我們的委託製造服務)銷售額為1.22億美元,按固定匯率下滑9%,反映與去年同期相比的比較基期較具挑戰。
Moving through the rest of the P&L. Our adjusted gross margin of 44.5% would represent a 100 basis points decline as compared to the prior year period, as benefits from our manufacturing improvements and portfolio initiatives were more than offset by lower U.S. sales of BREVIBLOC and cyclo and a less favorable product mix. In addition, gross margin was negatively impacted by incremental expenses related to enhancing manufacturing capabilities at our dialyzer facility.
接著看損益表其餘項目。我們調整後毛利率為44.5%,較去年同期下降100個基點;儘管製造改善與產品組合調整計畫帶來效益,但仍被美國BREVIBLOC與cyclo銷售較低以及較不利的產品組合所抵銷。此外,毛利率亦受到為提升透析器工廠製造能力而增加的額外費用所拖累。
Adjusted SG&A totaled $610 million, decreasing 5% on a reported basis and 1% on a constant currency basis, reflecting the positive contributions from our targeted initiatives to improve operational efficiency.
調整後銷售、一般及行政費用(SG&A)合計6.10億美元,按報告基礎下降5%,按固定匯率下降1%,反映我們針對提升營運效率的重點計畫帶來正面貢獻。
We continue to strategically invest in sales and marketing initiatives while maintaining our focus on driving increased effectiveness in general and administrative expenses.
我們在策略性投資銷售與行銷計畫的同時,仍維持聚焦於提升一般與行政費用的效能。
Adjusted R&D spend in the quarter of $141 million decreased 14% on a reported basis and 10% on a constant currency basis versus the prior year period. We continue to see benefit from our efforts to enhance our processes and optimize our R&D organization while prioritizing strategic investments in our innovation pipeline.
本季調整後研發(R&D)支出為1.41億美元,按報告基礎較去年同期下降14%,按固定匯率下降10%。我們持續受惠於強化流程與優化研發組織的努力,同時優先投入創新產品線的策略性投資。
Adjusted operating margin in the quarter was 18%, an increase of 90 basis points versus the prior year. Net interest expense totaled $20 million in the second quarter, an increase of $9 million compared to the prior year driven by lower interest income and increased interest expense, resulting from higher average commercial paper borrowings during the quarter and the issuance of our new $1.5 billion of euro-denominated debt. This debt was issued at an average coupon of 75 basis points and an average duration of 7.5 years.
本季調整後營業利益率為18%,較去年同期提升90個基點。第二季淨利息費用合計2,000萬美元,較去年增加900萬美元,主要因利息收入下降與利息費用上升所致;利息費用上升源於本季平均商業本票借款增加,以及我們新發行15億美元歐元計價債務。該債務的平均票面利率為75個基點,平均存續期間為7.5年。
Other income totaled $28 million in the quarter driven by pension benefits and foreign exchange gains on balance sheet positions. The adjusted tax rate was 10.8% for the quarter, favorable to our expectations, primarily driven by a benefit resulting from a favorable tax ruling along with stock compensation deductions.
本季其他收入合計2,800萬美元,主要受惠於退休金收益以及資產負債表部位的外匯收益。本季調整後稅率為10.8%,優於我們的預期,主要來自一項有利稅務裁定所帶來的利益,以及股票薪酬扣除額。
And as previously mentioned, adjusted earnings of $0.89 per diluted share exceeded our guidance of $0.80 to $0.82 per share. Within the second quarter, we repurchased approximately $123 million or 2 million shares of Baxter's stock, which was partially offset by option-related dilution within the quarter.
如先前所提,調整後每股稀釋盈餘0.89美元,超出我們每股0.80至0.82美元的指引。在第二季內,我們回購了約1.23億美元、約200萬股百特股票,但部分被本季與選擇權相關的稀釋所抵銷。
With respect to cash flow, in the first half of 2019, free cash flow of $265 million was in line with our expectations year.
就現金流而言,2019年上半年自由現金流為2.65億美元,符合我們的年度預期。
In the second quarter, we drove sequential improvement in days' inventory on hand, and we continue to expect the cash conversion ramp in the second half of the year.
第二季我們推動在手庫存天數的環比改善,且我們仍預期下半年現金轉換將加速提升。
Let me conclude my comments this morning by providing our guidance for the full year 2019 and the third quarter. For the full year 2019, we now expect reported growth of 1% to 2% globally and approximately 4% sales growth on both the constant currency and operational basis.
最後,讓我在今天上午以提供2019年全年與第三季的指引作結。就2019年全年而言,我們目前預期全球報告口徑成長1%至2%,且以固定匯率與營運口徑計算的銷售成長約為4%。
Moving to full year guidance by business on a constant currency basis except where otherwise noted. In Renal Care, we now expect growth of approximately 2%. Strong growth for our PD therapies globally is expected to be partially offset by lower sales in, in-center HD due to strategic exits in our U.S. bloodlines business, which negatively impacted Renal Care sales in 2019 by approximately $55 million.
接著說明各事業的全年指引(除非另有說明,均以固定匯率口徑)。在腎臟照護方面,我們目前預期成長約2%。我們的腹膜透析(PD)療法在全球的強勁成長,預期將部分被院內血液透析(in-center HD)較低的銷售所抵銷,原因是我們策略性退出美國血路管(bloodlines)業務,該舉措在2019年對腎臟照護銷售造成約5,500萬美元的負面影響。
In addition, the impact of supply disruption from the Revaclear dialyzer is expected to negatively impact full year sales by approximately $20 million. We expect to return to normal inventory level by the end of the year.
此外,Revaclear 透析器供應中斷的影響,預期將使全年銷售減少約2,000萬美元。我們預期在年底前恢復至正常庫存水位。
In Medication Delivery, we continue to expect sales to increase approximately 6% with sequential improvement in the second half of the year.
在藥物輸注(Medication Delivery)方面,我們仍預期銷售將成長約6%,且下半年將呈現環比改善。
For our Pharmaceuticals business, we now expect an increase of low single digits on a constant currency basis. U.S. cyclo sales are now expected to total approximately $125 million versus our previous assumption of $105 million. Adjusting for U.S. cyclo, operational growth is now expected to increase mid-single digits. As a reminder, BREVIBLOC sales are included in operational growth and are expected to decline approximately $75 million in 2019.
在製藥(Pharmaceuticals)業務方面,我們目前預期以固定匯率口徑計算將呈現低個位數成長。美國 cyclo 銷售目前預期約為1.25億美元,高於我們先前假設的1.05億美元。若排除美國 cyclo,營運成長目前預期將提升至中個位數。提醒一下,BREVIBLOC 的銷售包含在營運成長中,且預期2019年將下滑約7,500萬美元。
Moving to Clinical Nutrition. We continue to expect sales growth of approximately 3%. For our Advanced Surgery business, we now expect sales to increase high single digits given the strong performance year-to-date. Our guidance assumes the competitive supply constraints begin to ease in the third quarter.
接著是臨床營養(Clinical Nutrition)。我們仍預期銷售成長約3%。在先進外科(Advanced Surgery)業務方面,鑑於年初至今的強勁表現,我們目前預期銷售將成長高個位數。我們的指引假設競爭對手的供應限制將於第三季開始緩解。
For the Acute Therapies business, we continue to expect growth of approximately 7% to 8%.
在急性治療(Acute Therapies)業務方面,我們仍預期成長約7%至8%。
Finally, in our other business, we continue to expect sales to decline low to mid-single digits.
最後,在其他業務方面,我們仍預期銷售將下滑低至中個位數。
Moving down to P&L, we continue to anticipate adjusted operating margin expansion of 80 to 100 basis points with additional savings in operational expenses, being offset by the gross margin impact of mitigation efforts to return our dialyzer manufacturing plant to full capacity by year-end. The full year estimate of these incremental expenses is expected to total approximately $50 million.
往下看損益表(P&L),我們仍預期調整後營業利益率將擴張80至100個基點,來自營運費用的額外節省,但將被我們為使透析器製造工廠於年底前恢復滿載產能所採取的緩解措施對毛利率造成的影響所抵銷。這些增量費用的全年估計總額預期約為5,000萬美元。
We continue to expect net interest expense of approximately $65 million to $70 million, and we now expect adjusted other income of approximately $90 million for 2019.
我們仍預期淨利息費用約為6,500萬至7,000萬美元,且目前預期2019年調整後其他收入約為9,000萬美元。
For the year, we now expect an average adjusted tax rate of approximately 16%, reflecting the favorability from Q2. We continue to anticipate a full year diluted average share count of approximately 520 million shares. Based on these factors, we now expect 2019 adjusted earnings, excluding special items, of $3.34 to $3.40 per diluted share.
就全年而言,我們目前預期平均調整後稅率約為16%,反映第二季的有利因素。我們仍預期全年稀釋後加權平均股數約為5.20億股。基於上述因素,我們目前預期2019年調整後盈餘(不含特殊項目)為每股稀釋盈餘3.34至3.40美元。
Finally, for the year, we continue to expect to generate operating cash flow of $2.3 billion and free cash flow of $1.6 billion.
最後,就全年而言,我們仍預期將產生23億美元的營業現金流,以及16億美元的自由現金流。
Specific to the third quarter of 2019, we expect sales growth of 3% to 4% on a reported basis and approximately 5% on both a constant and an operational basis.
針對2019年第三季,我們預期以報告口徑計算的銷售成長為3%至4%,且以固定匯率與營運口徑計算均約為5%。
And we expect adjusted earnings, excluding special items, of $0.82 to $0.84 per diluted share.
我們也預期調整後盈餘(不含特殊項目)為每股稀釋盈餘0.82至0.84美元。
With that, we can now open the call to Q&A.
接下來,我們可以開始問答。
Operator
Operator
(Operator Instructions) I would like to remind participants that this call is being recorded, and a digital replay will be available on the Baxter International website for 60 days at www.baxter.com.
(接線員指示) 提醒各位與會者,本次電話會議將被錄音,且數位重播將於百特國際網站提供60天,網址為 www.baxter.com。
And our first question comes from David Lewis from Morgan Stanley.
第一個問題來自摩根士丹利(Morgan Stanley)的 David Lewis。
David Ryan Lewis - MD
David Ryan Lewis - MD
Joe, I thought your comments on ESRD are pretty clear. So maybe I'll focus on Medication Delivery, and a quick one for Jay. So Joe, in Med Delivery, obviously, you beat our number. There was a pretty significant momentum improvement. You're maintaining guidance. Could you just talk about how you are feeling about market stability, new customer or new account penetration and frankly, the pump business as we head into the second half of the year? And then a quick one for Jay.
Joe,我覺得你對 ESRD 的評論相當清楚。所以我可能把重點放在藥物輸注(Medication Delivery),另外也快速問 Jay 一題。Joe,在藥物輸注方面,很明顯你們的表現超出我們的數字。動能改善相當顯著。你們維持指引不變。能否談談你們對市場穩定性、新客戶或新帳戶滲透,以及坦白說,當我們進入下半年時對幫浦業務的感受如何?然後再快速問 Jay 一題。
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
David, the business, as we had predicted, had a really tough comp in the first quarter. But we had confidence in our ability to secure current customers that have been with us for many years. So we have -- we signed all GPO agreements and, for the most part, we signed a great deal of IDN agreements as well. The market is stable. We found opportunities to gain new customers, not only in the acute care market, but also in the OEM or contract manufacturing business that is important to us, help us in our facilities, but also improve the visibility of Baxter product line across all sets of care.
David,正如我們先前預測,該業務在第一季面臨非常艱難的比較基期。但我們對於鞏固那些多年來一直與我們合作的現有客戶的能力很有信心。因此我們已經——我們簽下了所有 GPO 協議,而且在很大程度上也簽下了相當多的 IDN 協議。市場是穩定的。我們也找到機會爭取新客戶,不僅在急性照護市場,也在對我們很重要的 OEM 或委託製造業務上;這不僅有助於我們的廠房運作,也提升百特產品線在各類照護場景中的能見度。
When it comes to pumps, we have a very healthy pipeline. There's always pluses and minuses, but I would say, at the moment, the pluses are winning pretty handily the opportunities that we have. But I would tell you, the new management group that we have put in the U.S. has done an extraordinary job in understanding the pipeline, in the creation of value. Our Spectrum version 9 is a wonderful pump. It's a really good device with the #1, best-in-class drug library. And that has been very important to us in terms of having this product showcased for our customers. So the business, as we predicted, is healthy. We're going to continue to make progress. And this continues to be a source of investment for us as our new pump platform is coming along extremely well, and we're very comfortable with the launch time line for it.
至於幫浦,我們有非常健康的案源管線。一向有利有弊,但我會說,就目前而言,利多相當明顯,且我們手上的機會多半進展順利。不過我也要告訴你,我們在美國新建立的管理團隊,在理解管線與創造價值方面做得非常出色。我們的 Spectrum 第9版是一款很棒的幫浦。它是一個非常優秀的裝置,具備同級最佳、排名第一的藥品資料庫。這對我們而言非常重要,因為能讓客戶看到並體驗這項產品。因此,正如我們所預測,這項業務是健康的。我們將持續取得進展。隨著我們的新幫浦平台推進得非常順利,這仍將是我們的投資重點之一,而我們對其上市時程也非常有信心。
David Ryan Lewis - MD
David Ryan Lewis - MD
Okay. Very clear. And then Jay, just thinking about a couple of items in the guidance for the back half of the year. I mean FLOSEAL was a benefit to this particular quarter. I'm sort of curious, what your assumptions were for the back half of the year for FLOSEAL? And then with Myxredlin, maybe just talk a little briefly about the size of the opportunity there for the company. I think we've talked about this product launch for a while. How big is that opportunity? And what are the assumptions into the back half?
好的。非常清楚。接著,Jay,我想就下半年指引中的幾個項目請教。我的意思是,FLOSEAL 在這一季對業績有幫助。我有點好奇,你們對下半年 FLOSEAL 的假設是什麼?另外關於 Myxredlin,能否也簡要談談這對公司而言的機會規模?我想我們談這個產品上市已經有一段時間了。這個機會有多大?以及對下半年的假設是什麼?
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
Sure. With respect to our BioSurgery business, yes, we did comment on some upside that we experienced in the second quarter. We don't like to forecast competitor outages, so we don't maintain long-term assumptions on that. However, if we have very clear visibility to a short-term situation emerging, we will reflect that in our guidance. So as we think about Advanced Surgery, there's roughly 2 months of upside that we're counting on in our numbers, as we sit here today. So we'll expect that to continue for a couple of months. If it continues further than that, of course, we will be available to supply our customers. But we are not counting on anything more than that. We've talked previously about how exciting the insulin Myxredlin launch is. It's a new presentation of a workhorse product for hospitals, absolutely thrilled. The size of the market is significant. It's over $100 million market, I mean, hospitals in the U.S. So this represents a very viable, long-term opportunity for us.
當然。就我們的 BioSurgery 業務而言,是的,我們確實提到第二季出現了一些上行空間。我們不喜歡去預測競品的供應中斷,因此不會對此維持長期假設。不過,如果我們對某個短期情況的出現有非常清楚的能見度,我們會把它反映在指引中。因此,當我們思考 Advanced Surgery 時,以我們目前所掌握的情況來看,我們在數字中納入了大約 2 個月的上行空間。所以我們預期這種情況會再持續幾個月。如果持續時間更長,當然,我們也會隨時準備好供應客戶。但我們不會把超過這部分的情況納入預期。我們先前談過胰島素 Myxredlin 上市有多令人振奮。這是醫院常用主力產品的一種新劑型/新呈現方式,我們非常興奮。市場規模相當可觀。在美國醫院端,這是一個超過 1 億美元的市場。因此,這對我們而言是一個非常可行的長期機會。
As it relates to this year's guidance, we have single-digit millions built in -- basically, nothing built into our guidance at this point. In large part, we want to be cautious in terms of launch timing preparing and having adequate supply available when we actually go to market. So no meaningful impact this year, but stay tuned as we give guidance for 2020. This will have a more meaningful impact in those numbers.
就今年的指引而言,我們只納入了個位數百萬美元的貢獻——基本上,目前在指引中幾乎沒有納入任何東西。很大一部分原因是,我們希望在上市時點上保持謹慎,並在真正推向市場時做好準備、確保有充足供應。因此今年不會有顯著影響,但請持續關注我們對 2020 年的指引。它在那些數字中將會帶來更有意義的影響。
Operator
Operator
And our next question comes from Robbie Marcus from JPMorgan.
下一個問題來自摩根大通(JPMorgan)的 Robbie Marcus。
Robert Justin Marcus - Analyst
Robert Justin Marcus - Analyst
And again congrats on a nice quarter here. Jay, 2 questions for you. First, maybe, we could start on the P&L performance. Really impressive how you're able to offset some of the lower gross margin product strength in the quarter with lower R&D and SG&A. But with R&D taking such a hit and SG&A coming down so rapidly, maybe you could just give us some insight into where that's coming from? Is it more general efficiency and overhead? Or are you holding back on some projects for the future?
再次恭喜本季表現亮眼。Jay,我有兩個問題。首先,也許我們可以從損益表(P&L)表現談起。你們能用較低的研發與銷管費用(R&D 與 SG&A)來抵消本季部分低毛利產品占比提升的影響,這點非常令人印象深刻。但研發費用降幅這麼大、銷管費用也下降得這麼快,能否請你分享一下主要原因?是更一般性的效率提升與間接費用降低嗎?還是你們把某些專案延後到未來?
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
Sure. Just with respect to gross margin. To your comment, gross margin did come in a little bit below our expectations. Really, there were just a few drivers of that. Some of it relates to business mix, as you pointed out. We had very strong performance in our drug compounding business, but that carries a much lower margin than the corporate average. Now interestingly enough about this business, it is a very high return on invested capital business for us, but the gross margin is lower. So the fact that we overachieved, that business costs us about 30 basis points to our gross margin. And then addressing some of the dialyzer manufacturing issues, that's roughly a 20 basis point impact in the quarter. So those were 2 of the more prominent items impacting gross margin for us. Of course, there are always other bits and bytes. As we look -- but we were able to offset that with continued focus on spending.
當然。先談毛利率。如你所說,毛利率確實比我們預期略低一些。主要只有幾個驅動因素。其中一部分與業務組合有關,正如你指出的。我們的藥品調配(drug compounding)業務表現非常強勁,但其毛利率遠低於公司平均。有趣的是,這項業務對我們而言是投入資本報酬率(ROIC)非常高的業務,但毛利率較低。因此,該業務超預期的表現,對我們毛利率造成約 30 個基點的拖累。另外,處理透析器(dialyzer)製造方面的一些問題,本季約影響 20 個基點。所以這兩項是影響我們毛利率較為顯著的因素。當然,還會有其他零星因素。但我們也透過持續聚焦費用支出來抵消這些影響。
And so on the SG&A side, we are very focused on improving the efficiency of our back-office operations, along with judiciously spending every single dollar. So we've talked in the past about the zero-based spending approach that we have here, disciplined around all spending categories, along with really thinking creatively about how we organize the back office. That continues to pay dividends today, paid dividends in the quarter. You saw a decline of SG&A of 1%. And again, this is on the back of 3 or 4 years of continued improvements in this particular area. So a great performance on the SG&A line.
在銷管費用(SG&A)方面,我們非常專注於提升後勤/後台(back-office)營運效率,同時審慎地花好每一塊錢。我們過去談過採用零基預算(zero-based spending)的方式,對所有支出類別都保持紀律,並且以更有創意的方式思考如何組織後台。這些作法至今仍持續帶來成效,本季也同樣有所貢獻。你看到 SG&A 下降了 1%。而且這是在過去 3 到 4 年持續改善這個領域的基礎之上。因此 SG&A 這一行的表現非常出色。
R&D is a little bit different. Some of this relates to timing. Some of it relates to the fact that we've been able to get after some of the infrastructure cost in R&D faster than accelerations in certain areas in new product spending. And so we will see some R&D tick up in the second half of the year. What I will tell you is our overarching principle on R&D is, we want to invest to grow, and we are funding programs for success. We are not holding back on any dollars. And I think the press release, Joe's comments about the spirit of innovation at the company is evident of that philosophy in action. Having said that, we did see savings in this particular area. So stay tuned to the back half. Joe, you want to add to that?
研發(R&D)則有些不同。其中一部分與時點有關。另一部分是因為我們在研發的基礎設施成本上,能比某些領域新產品支出加速更快地取得成效。因此我們會看到下半年研發費用略有回升。我想強調的是,我們對研發的總體原則是:我們要投資以成長,並為成功提供資金支持。我們沒有在任何預算上縮手。我認為新聞稿中 Joe 對公司創新精神的評論,也體現了這個理念正在落實。話雖如此,我們確實在這個領域看到一些節省。所以下半年請持續關注。Joe,你要補充嗎?
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Yes. Sure. Robbie, the whole thing about R&D was for us to create efficiency in the R&D line. And the spending has not been very different than, if you go back to 2016, it's just a mix where we're spending and how we're spending the money. So we abandoned large programs that had absolutely no return on investment. And we invest in significant opportunities in areas of Medication Delivery, acute renal care with our point-of-care in PD as well as some very quick turnaround new products in Advanced Surgery, some in the Nutrition area.
是的。當然。Robbie,關於研發,我們的重點是提升研發費用線的效率。如果你回頭看 2016 年,其實支出水準並沒有差很多,差別在於我們把錢花在哪裡、以及怎麼花。我們放棄了那些完全沒有投資報酬的龐大專案。我們則投資於具重大機會的領域,包括藥物輸送(Medication Delivery)、急性腎臟照護(acute renal care)中我們在 PD 的即時檢測(point-of-care),以及 Advanced Surgery 中一些能快速推出的新產品,還有營養(Nutrition)領域的一些項目。
So if you think about -- we also have significant arbitrage in labor because we've created centers of excellence across the globe. But also now we have a very large center in Bangalore, India, we never had. So it is a well-managed group. Our heads of R&D, led by our GPO leaders and Sumant Ramachandra, who is the -- has overarching responsibility for the function, have been very successful in reallocation of costs. So I want to just tell our investors that we're very focused in innovation and that fluctuation in spending is nothing other than being efficient and timings of the investments has nothing to do with us going and tightening the belt in R&D programs.
另外,如果你想一想——我們在人力方面也有顯著的套利空間,因為我們在全球建立了卓越中心(centers of excellence)。而且我們現在在印度班加羅爾(Bangalore)有一個非常大的中心,過去是沒有的。因此這是一個管理良好的團隊。我們的研發主管,在我們的 GPO 領導者以及對該職能負總責的 Sumant Ramachandra 帶領下,在成本重新配置方面非常成功。所以我想告訴投資人,我們非常聚焦於創新,而支出波動只是效率提升與投資時點的結果,與我們去收緊研發專案的預算完全無關。
Robert Justin Marcus - Analyst
Robert Justin Marcus - Analyst
Very clear. And if I could sneak one more in. Just on capital deployment, not surprised that we haven't seen any M&A here with MedTech valuations where they are. But how are you balancing your capital allocation plans here with Baxter's share price set at highs and MedTech valuations where they are?
非常清楚。如果我可以再偷偷加問一題。就資本部署而言,考量到目前醫療科技(MedTech)估值所在的水位,我不意外我們還沒看到任何併購(M&A)。但在百特(Baxter)股價處於高檔、同時醫療科技估值又在目前這個水位的情況下,你們如何在此平衡資本配置計畫?
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Robbie, it has been a very, very busy first half analyzing opportunities. The way we allocate capital inorganically is not very different than how we allocate organically. We do have focus in the area of monitoring, in the areas of acute renal care and critical care. We also are very focused in looking at individual molecules. So what I'm going to -- I say to our investors is think about Baxter adding value with the small tuck-ins, as we look for the right opportunity and valuation for a larger deal. It is very, very rich, right now the market is frothy, and we are not going to compromise on the returns of these acquisitions.
Robbie,上半年我們在分析機會方面非常、非常忙碌。我們以非有機方式配置資本的方法,和我們以有機方式配置資本的方法並沒有太大不同。我們確實聚焦在監測領域、急性腎臟照護以及重症照護等領域。我們也非常專注於評估個別分子。所以我想說的是——我對投資人說,請把百特的增值想成是透過小型補強式併購(tuck-ins),同時我們也在尋找更大型交易的合適機會與估值。目前估值非常、非常昂貴,市場也相當火熱,我們不會在這些收購的報酬上妥協。
Every acquisition has -- the larger they get, the inherent risk is enormous. And we all understand that. We all take risks. But there is a point where the cost of investing in that asset and the price and valuations are so out of whack that you cannot make internal rate of return of low single digits. It doesn't work. It doesn't work. And then anything goes wrong, the FDA comes about and tells that a product that you have has a compound that is made into the product that doesn't work. Now your whole valuation of that target is under scrutiny. You've got to be very careful with this and understand your guidance.
每一筆收購——規模越大,其內在風險就越巨大。我們都明白這一點。我們都會承擔風險。但當投資該資產的成本、價格與估值嚴重失衡到你連低個位數的內部報酬率(IRR)都做不出來時,就會有一個臨界點。行不通。行不通。然後只要任何事情出錯,例如 FDA 出面告訴你,你所擁有的一項產品含有某種化合物、被製成產品後卻不起作用。那麼你對該標的的整體估值就會受到檢視。你必須非常小心,並且理解你的指引。
I think Baxter is surprising to our investors how much opportunity there was and there is and there will be in our base businesses and how we have the opportunity to innovate and continue to maintain #1 position in most of our businesses and watch us in the pump business, watch us there because we're coming out with a great platform of pumps and monitoring devices. So the thing is let's add to those inorganically as tuck-ins. Let's not think about all the time this huge capital investment and allocation into assets that are overly expensive.
我認為百特讓投資人感到意外的是,我們的核心業務過去有、現在有、未來也會有這麼多機會,以及我們如何有機會創新並持續在多數業務中維持第一名的地位;也請關注我們的幫浦業務,關注那裡,因為我們將推出一個很棒的幫浦與監測裝置平台。所以重點是,讓我們透過補強式併購把這些能力以非有機方式加上去。不要總是去想把大量資本投資與配置到那些過度昂貴的資產上。
Then I'll tell you something else, we will continue to acquire our shares prudently when we see the prices are there because we're not going to sit on cash. As I said to you, cash is not going to burn a hole in our pockets.
另外我再告訴你一件事,當我們看到價格合適時,我們會持續審慎地回購自家股票,因為我們不會把現金放著不用。如我跟你說的,現金不會在我們口袋裡燒出一個洞。
Operator
Operator
And our next question comes from Bob Hopkins from Bank of America.
下一個問題來自美國銀行(Bank of America)的 Bob Hopkins。
Robert Adam Hopkins - MD of Equity Research
Robert Adam Hopkins - MD of Equity Research
Wanted to start with a big picture question. Joe, I mean, obviously, you've put up a very solid Q2. It sounds like the pipeline is making good progress. Obviously, also during the quarter, you got some nice new sort of structural tailwinds in some of your businesses. As you kind of think about all of these factors and put them together, do they sort of suggest some upward pressure to your long-range plan from a revenue growth perspective? Or are they just nice offsets to other headwinds? Just trying to get a sense for the sort of cumulative effect of all these things that are going on right now?
我想先從一個宏觀問題開始。Joe,我是說,很明顯你們第二季(Q2)交出非常穩健的成績。聽起來產品管線進展良好。而且很明顯在本季期間,你們部分業務也獲得了一些不錯的、偏結構性的順風因素。當你把這些因素放在一起思考時,是否意味著從營收成長角度來看,你們的長期計畫可能面臨一些上行壓力?還是說它們只是對其他逆風的良好抵銷?我只是想了解一下,這些目前正在發生的事情加總起來的整體效果大概是什麼?
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Well if you think about our long-range plan, when you give a 5-year plan, you're always going to have puts and takes on how you're going to make things happen, okay? You have the best intentions in the world, you have the best plans in the world, not everything works the same way on the positive side and negative side. So for instance, we didn't plan to have our insulin product premixed approved as early as we did. We planned actually to have that approval towards the end of the year. That's a plus for us, right?
如果你想想我們的長期計畫,當你提出一個五年計畫時,你總會在如何讓事情發生上有利有弊、此消彼長,好嗎?你有全世界最好的意圖、最好的計畫,但不是所有事情在正面與負面都會以同樣方式發展。例如,我們並沒有規劃我們的預混胰島素產品會這麼早獲得核准。我們原本其實是規劃在年底左右才取得核准。這對我們來說是加分,對吧?
But other things work the other way as well. So when I look at the major forces that we have going on right now, you have a tremendous momentum in our peritoneal dialysis business. So you know, just in terms of patient growth, we are experiencing a healthy growth in terms of patients without even having the executive order from the White House coming in and becoming a rule and that will be transformational for the Renal business. But just that where we experienced high single-digit growth in patients in PD. So that has an effect to our plan that offsets many, many negatives that can appear in the future. So I feel at this moment that between everything that is happening in the market and the things that are happening in Baxter, that we cannot sit here and say what we told you last year we reconfirm today, okay?
但其他事情也可能往相反方向發展。所以當我看我們目前正在發生的主要力量時,你會看到我們的腹膜透析(PD)業務有非常強的動能。所以你知道,就病患成長而言,即使白宮的行政命令尚未落地成為規則——而那將對腎臟業務帶來變革性影響——我們的病患數仍在健康成長。也就是說,我們在 PD 的病患數呈現高個位數成長。因此,這會對我們的計畫產生影響,並抵銷未來可能出現的許多、許多負面因素。所以我此刻的感受是,在市場正在發生的一切與百特正在發生的事情之間,我們不能坐在這裡說:我們去年告訴你們的內容,今天我們再度確認,好嗎?
Robert Adam Hopkins - MD of Equity Research
Robert Adam Hopkins - MD of Equity Research
Okay. That sounds fair. But I'm just -- maybe as my second question, I'll just ask a follow-up to that. Because it -- I understand the philosophy, but it does seem like there is -- your philosophy in providing your guidance, but it does seem like -- since you gave that guidance, most of the incremental news flow that you've been getting in your business is positives. I mean -- and I just want to make sure I'm not missing anything. When we think long term, are there other negatives that have popped up that would make you hesitant on this issue relative to some of these very incrementally positive pieces of news that you've gotten over the course of the last couple of months?
好的。聽起來合理。但我只是——也許作為我的第二個問題,我想就此追問一下。因為——我理解你們提供指引的理念,但看起來——自從你們給出那個指引以來,你們業務收到的大多數新增消息流都是正面的。我的意思是——我只是想確認我沒有漏掉什麼。從長期來看,是否還出現了其他負面因素,會讓你們在這個議題上更為保守,相較於過去幾個月你們所獲得的這些逐步偏正面的消息?
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
Remember, the last time we gave guidance, the dynamic in the Medication Delivery business shifted quite a bit. And we've been able to reconfirm our long-term expectations despite that shift as a result of strength in many different areas in the portfolio and general buoyancy of the new product pipeline along with great product progress in areas like PD and successful adoption there. So look, I think it's too early to start changing LRPs at this point. We'll consider doing that at some point in the future. But on balance, we were very pleased with the quarter, we were pleased with the signs of operational strength along with some of the longer-term good pieces of news that we've been able to either de-risk or add to the story.
請記得,我們上一次給出指引時,藥物輸送(Medication Delivery)業務的態勢出現了相當大的轉變。而我們之所以仍能在那樣的轉變下重申長期預期,是因為產品組合中許多不同領域的強勁表現,以及新產品管線的整體韌性,同時也包括像 PD 這類領域的產品進展良好並成功被採用。所以你看,我認為現在就開始調整長期規劃(LRPs)還太早。我們會在未來某個時間點考慮這麼做。但整體而言,我們對本季非常滿意;我們也很高興看到營運面的強勁跡象,以及一些較長期的利多消息——我們已經能夠降低其風險(de-risk)或把它們納入整體論述。
Operator
Operator
And our next question comes from Joanne Wuensch from BMO Capital markets.
下一個問題來自 BMO Capital Markets 的 Joanne Wuensch。
Joanne Karen Wuensch - MD & Research Analyst
Joanne Karen Wuensch - MD & Research Analyst
I want to spend a couple of more minutes on the Renal business, and this is sort of a 2-part question. The first part is you've been sort of huddling a headwind, as you've exited the HD business, the in-center HD business. At what stage does that annualize and we don't see that anymore? And then the second part is your $500 million investment. Can you just sort of parse out a little bit what do you think the benefit would be? And then I would assume there's some level of pressure on gross margins, how we can think about that over time?
我想再花幾分鐘談談腎臟業務,這算是一個兩部分的問題。第一部分是,當你們退出血液透析(HD)業務、也就是院內(in-center)HD 業務時,你們一直在承受某種逆風。這個影響到什麼階段會年化(annualize),然後我們就不會再看到它了?第二部分是你們的 5 億美元投資。你能否稍微拆解一下,你認為它會帶來什麼效益?然後我假設毛利率會有某種程度的壓力,我們該如何隨時間推移來看待這件事?
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
Sure. Just -- I'll make a comment on the bloodlines and then Joe, maybe you can comment on the excitement around the investment. With respect to the bloodlines, that's just 1 component of the HD business in the U.S. We do have other [adds] products that we sell in the U.S. But that particular one was a product that we distributed and it was a very low-margin business. It was a $55 million impact roughly for this year. And by the end of this year, it will be done. And it will be -- cease to be a headwind at the end of this year. As it relates to the investment, Joe, you want to make some comments about that?
當然。我先就血液管路(bloodlines)做個評論,然後 Joe,也許你可以談談市場對這項投資的興奮度。就血液管路而言,那只是我們在美國 HD 業務的一個組成部分。我們在美國也有其他 [adds] 產品在銷售。但那一項是我們負責經銷的產品,而且毛利非常低。今年大約影響 5,500 萬美元。到今年年底就會結束。而且到今年年底,它將會——不再成為逆風。至於投資這件事,Joe,你要不要補充幾點?
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Sure. We have, to the best of our ability, scoped a project to -- based on interpretation of the executive order that we have, okay? And that is not final rule yet and there will be -- comments will be complete in about 50 days. And after that, the HHS has time to put the rule in place. So based on what we know and interpreted from the executive order, we have a 3-phase investment here. We have an investment where we can supply the market with the growth that is projected in the beginning because it's the progressive -- remember, this addresses the best market about 50% of the overall served market. And then from that 50%, there is a ramp. There is a period where clinics are given an opportunity to change their patterns between clinic hemodialysis and home therapy. So based on that, we can accommodate with some supply chain that we did extremely well about 1.5 years ago by relocating and reregistering products from all over the Americas. So we can do that.
好的。我們已在能力所及範圍內,根據我們手上行政命令的解讀,界定了一個專案範圍,好嗎?而那還不是最終規則,接下來會有——意見徵詢大約在 50 天內完成。之後,HHS 會有時間把規則落地。因此,基於我們所知並從行政命令解讀到的內容,我們這裡有一個三階段投資。我們有一項投資,能在一開始就依照預期成長來供應市場,因為這是逐步推進的——記得,這項措施涵蓋的是最佳市場,大約占整體可服務市場的 50%。然後在這 50% 裡面,會有一個爬坡。會有一段期間,診所被給予機會在院內血液透析與居家治療之間調整其模式。因此基於這點,我們可以透過供應鏈來因應;大約 1.5 年前我們做得非常好,透過把美洲各地的產品重新配置並重新註冊。所以我們可以做到。
Then there is a second phase where we do a small investment, more modest than $500 million that give us incremental capacities all the way then to start investing into a new plant. The investment will be -- depends upon the time, sometimes concurrently done. But the effect of the throughput will be felt later -- in later years. Remember, this is a 7-year program. So we feel, as a company, our responsibility, more responsibility to our customers and more so to the patients, is to be there for this opportunity. So we're going to make everything possible to not be a problem during the ramp-up that is so aggressively laid out in the executive order.
接著是第二階段,我們會做一個小規模投資,比 5 億美元更為保守,讓我們獲得額外產能,並一路推進到開始投資新廠。這項投資將會——取決於時程,有時會同步進行。但產出吞吐量的效果會在之後——在較後面的年度才會顯現。記得,這是一個 7 年期計畫。因此我們認為,作為一家公司,我們對客戶、尤其對病患,有責任把握這個機會並到位支援。所以我們會盡一切可能,確保在行政命令中如此積極規劃的爬坡期不會成為問題。
Operator
Operator
And our next question comes from Vijay Kumar from Evercore ISI.
下一個問題來自 Evercore ISI 的 Vijay Kumar。
Vijay Muniyappa Kumar - MD
Vijay Muniyappa Kumar - MD
Congrats on a nice piece here, Joe and Jay. Jay, maybe on the 3Q EPS. If I just look at the optics right, the last 2 years, EPS has grown sequentially, revenues are accelerating in the back half and sequentially, I'm not sure why EPS would be down because it looks like the dialyzer impact on gross margins was felt in 2Q. So maybe can you just walk through that EPS math and maybe some timing element on the expense here, which could be impacting 3Q?
恭喜你們拿出一個很不錯的成果,Joe 和 Jay。Jay,想請教一下第三季 EPS。如果我只看表面現象,過去兩年 EPS 都是逐季成長,下半年營收也在加速、且逐季走高;我不太明白為什麼 EPS 會下滑,因為看起來透析器(dialyzer)對毛利的影響在第二季就已經反映了。所以你能否帶我們走一遍 EPS 的計算邏輯,並談談是否有一些費用時點因素,可能影響第三季?
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
Sure. As we look at the Q2 to Q3 story, there are a couple of factors to keep in mind: one is the dialyzers impacted us about $0.01 in Q2, but as we move to Q3, that will ramp up a little bit, somewhere between $0.02 and $0.03 of impact. The second prominent driver relates to tax rate. We'll see a really substantial uptick in tax from Q2 to Q3. That's somewhere around $0.08 or $0.09. So it really does max some of the strong operational performance. Now I have to say, hats off to the tax team for great work in terms of optimizing the tax rate and allowing us to capitalize on opportunities that emerge and really think about how we organize our operations effectively in a tax-efficient manner. So we saw a benefit in Q1 and Q2, but we don't expect to see that in Q3 and Q4 to the same extent. So the tax rate in the third and fourth quarter kicks up to roughly about 19-ish percent from the 12-ish percent that we've had year-to-date.
好的。我們看第二季到第三季的變化,有幾個因素要記住:第一,透析器在第二季對我們的影響約為 0.01 美元,但進入第三季後,影響會再上升一些,大約在 0.02 到 0.03 美元之間。第二個主要驅動因素與稅率有關。我們會看到從第二季到第三季稅負大幅上升。大約影響 0.08 或 0.09 美元。所以它確實抵消了部分強勁的營運表現。我也要說,向稅務團隊致敬,他們在優化稅率方面做得非常出色,讓我們能把握出現的機會,並真正思考如何以具稅務效率的方式有效組織我們的營運。因此我們在第一季與第二季看到一些好處,但我們預期第三季與第四季不會在同樣程度上出現。所以第三季與第四季的稅率會從年初至今約 12% 左右,回升到約 19% 左右。
So that's really the -- those are some of the primary drivers. We'll see continued operational strength that helps support and offset those items. But that really is a big -- those are the big drivers as we move from Q2 to Q3.
所以這就是——這些是一些主要驅動因素。我們會看到持續的營運強勁表現,有助於支撐並抵消上述項目。但從第二季到第三季,這些確實是主要——主要驅動因素。
Vijay Muniyappa Kumar - MD
Vijay Muniyappa Kumar - MD
That's really helpful, Jay. And one quick on the Pharma. I mean BREVI was about 700, 800 basis points impact of revenue in the first half. Despite that you guys did phenomenal in Pharma rates, and as those headwinds go away in the back half, I'm just curious why perhaps Pharma couldn't come in better?
這很有幫助,Jay。再快速問一個關於製藥(Pharma)。我的意思是,BREVI 在上半年對營收的影響大約是 700、800 個基點。儘管如此,你們的 Pharma 成長率表現仍然非常亮眼;而且這些逆風在下半年消退後,我只是好奇為什麼 Pharma 可能不會更好?
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
As we look at the Pharmaceutical's business, to your point, we've had a very solid performance in the first half of the year. And a lot of that was driven by great performance in our compounding business outside the U.S. We do expect that -- and that business grew in the first half of the year in 20-ish percent, very significant.
就製藥業務而言,如你所說,我們在上半年表現非常穩健。其中很大一部分是由我們在美國以外的配製(compounding)業務的優異表現所帶動。我們確實預期——而且該業務在上半年成長約 20% 左右,非常顯著。
As we moved to Q3 and Q4, we don't expect to see that level of accelerated performance in the back half. So that really is the primary driver that takes the Pharma growth rate down. But I will tell you, we're very pleased with the performance in this area. It's been a great source of overachievement for us and steady growth. And with things like Myxredlin on the horizon, which will benefit future years, along with some of the premix injectables and the Claris portfolio, which has been selling well here in the U.S., overall, this has been a very solid performer for us.
進入第三季與第四季後,我們不預期下半年還會看到那樣的加速表現。因此這就是使 Pharma 成長率下滑的主要原因。但我可以告訴你,我們對這個領域的表現非常滿意。它一直是我們超預期達成與穩健成長的重要來源。而且像是即將推出的 Myxredlin,將在未來年度帶來助益;再加上一些預混注射劑(premix injectables)以及在美國這邊銷售表現良好的 Claris 產品組合,整體而言,這一直是我們非常穩健的表現來源。
Operator
Operator
And our next question comes from Lawrence Biegelsen of Wells Fargo.
下一個問題來自富國銀行(Wells Fargo)的 Lawrence Biegelsen。
Lawrence H. Biegelsen - Senior Analyst
Lawrence H. Biegelsen - Senior Analyst
Just one on infusion system and one on Asia-Pacific. So Joe, one of your competitors had some issues with their pump and infusion sets. Do you see an opportunity for Baxter to take some share here? And with the new pump platform coming out in 2020, are customers extending the selling cycle to wait for the new platform? And I have a one follow up.
我有一個關於輸注系統(infusion system)以及一個關於亞太地區的問題。Joe,你們的一位競爭對手在他們的幫浦與輸注管路(infusion sets)上出了一些狀況。你是否看到 Baxter 在這裡取得一些市占的機會?另外,新的幫浦平台將在 2020 年推出,客戶是否會延長銷售週期、等待新平台?我還有一個追問。
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Larry, the opportunities that we're having are mostly, mostly, related to the strength of our -- version 9 of our pump, its operability, its drug library. So we have customers who have been our customers for a long time and it's not for them to renew, they like the innovation and evolution of the product and they just buy it. There is always opportunity when there is a problem with a competitor in the market if that problem is perceived to be more prominent than temporary. So we need to think about, as we look at our Advanced Surgery business, that is going to be probably a temporary gain until the competitor comes back on the market. And because our product is so good, the FLOSEAL is the best product on the market, there's opportunity to retain accounts, right?
Larry,我們目前看到的機會多半、多半與我們——第 9 版幫浦的優勢有關,包括其可操作性與藥物資料庫(drug library)。所以我們有一些長期客戶,到了該續約的時候,他們喜歡產品的創新與演進,就直接購買。當市場上競爭對手出現問題時,若該問題被認為不只是短暫的,通常都會有機會。因此我們在看我們的先進外科(Advanced Surgery)業務時要思考,這可能只是暫時性的增量,直到競爭對手回到市場。而且因為我們的產品非常好,FLOSEAL 是市場上最好的產品,所以也有機會留住客戶帳戶,對吧?
So the same applies for the infusion pumps. It depends upon how permanent, how temporary the issues that competitors are having. But I think the success that we've been having is, first of all, a very good sales effort, new team, completely focused on pipeline. Second is the ability to demonstrate the technical superiority of our drug library compared to the competitors.
因此,同樣的情況也適用於輸注幫浦。這取決於競爭對手所面臨的問題是多麼永久、或多麼暫時。但我認為我們之所以能取得成功,首先是非常出色的銷售執行,新團隊,完全聚焦於銷售管線。第二是我們能夠展示,相較於競爭對手,我們的藥物資料庫在技術上的優越性。
To your point, on the new pump platform, no, the customers who need the product now, they'll take the product now. I just want to let you know that LVP, which is a large volume parenteral pump, which is what we have today. Remember, we don't have any other pump and that's what we have today. The guts of the new pump are different, are more modern and will be a horizontal pump. But the workflow, the drug library, all the features are the same. Meaning, you have a new product with phenomenal operability, but also has a great pumping mechanism in the new pump platform. We have a great pump mechanism today in version 9 and the operability is the same.
就你提到的新幫浦平台而言,不,現在就需要產品的客戶,他們會現在就採用產品。我只是想讓你知道,LVP,也就是大容量靜脈注射幫浦,就是我們目前所擁有的產品。請記得,我們沒有其他幫浦,今天我們就是只有這個。新幫浦的核心結構不同、更現代化,並且會是水平式幫浦。但工作流程、藥物資料庫以及所有功能都相同。也就是說,你會有一個操作性極佳的新產品,同時在新幫浦平台上也具備很棒的幫浦機構。我們目前在第9版就已經有很棒的幫浦機構,而操作性是相同的。
So the customers have a lot to gain when Baxter launches the other pumps, which are probably the same family with the same interoperability. So it'd be a new platform on the market that has that capability. And I think the customers can see that going forward. If they need a pump now, there's nothing that they're losing on this current version versus the new platform with a large volume parenteral, but what we are bringing to the market is not only syringe with patient-controlled analgesia, PCA, as well as in 12 months from the launch of the first one, is ambulatory. So I hope this answers your question and put our investors at ease that there is no business being postponed because we don't have the NPP today.
因此,當百特推出其他幫浦時,客戶將有很大的收穫;那些幫浦很可能屬於同一產品家族,並具備相同的互通性。所以市場上會出現一個具備該能力的新平台。我認為客戶也能看見未來的發展方向。如果他們現在需要幫浦,使用目前這一版的大容量靜脈注射幫浦,與新平台相比並沒有任何損失;但我們將帶到市場的不僅是注射器式幫浦搭配病人自控鎮痛(PCA),而且在第一款產品上市後12個月內,還會推出可攜式(ambulatory)。所以我希望這回答了你的問題,也讓投資人放心:不會因為我們今天沒有NPP而導致業務被延後。
Lawrence H. Biegelsen - Senior Analyst
Lawrence H. Biegelsen - Senior Analyst
Very helpful, Joe. And just lastly, Asia-Pacific has been very strong. What's driving that? And how sustainable is that?
非常有幫助,Joe。最後一個問題,亞太地區表現非常強勁。是什麼在驅動?而這樣的表現有多可持續?
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
Great. We're really pleased with the performance in the Asia-Pacific region, 9% growth coming, was really strength across-the-board. We grew in accustomed to solid performance coming from China in the quarter, 7-plus percent growth from that particular business. But what perhaps has been more surprising based on historical commentary from Baxter is the fact that we had tremendous performance in Japan, high single-digit growth coming from our Japanese business. And this -- it's really a combination of factors in play.
很好。我們對亞太地區的表現非常滿意,成長9%,基本上是全面性的強勁。本季我們延續了來自中國的穩健表現,該業務成長超過7%。但或許更令人意外、也與百特過去的評論相比不同的是,我們在日本的表現非常出色,日本業務帶來高個位數成長。而這——其實是多項因素共同作用的結果。
And looking at the other areas, solid performance in Southeast Asia. We've had a great business in Australia, New Zealand, for the math, we've been there for many, many years, double-digit growth there. A lot of that benefiting from compounding. But what I will tell you is this is a combination of commercial execution along with the benefits of new product launches. We've talked quite a bit about the impact of KAGUYA. We're seeing continued momentum in patient gains in Japan. And this is -- that's a great driver for us. But I think across the region, there are examples of innovation, but, like I said, commercial excellence that have really contributed to this performance.
再看其他地區,東南亞表現穩健。我們在澳洲、紐西蘭也有很好的業務,坦白說,我們在那裡已經很多很多年了,當地呈現雙位數成長。其中很大一部分受惠於複利效應。但我要說的是,這是商業執行力與新產品上市效益相結合的結果。我們已經談了不少KAGUYA的影響。我們在日本看到病人數持續增加、動能延續。而這——對我們來說是很重要的驅動力。但我認為在整個區域內,有創新的例子,同時也如我所說,商業卓越確實促成了這樣的表現。
On a full year basis, we'll expect this to come down a little bit from a growth rate standpoint, but not materially. So overall, great performance from the team in Asia.
以全年來看,我們預期從成長率角度會稍微回落一些,但不會有實質性的變化。總體而言,亞太團隊表現非常出色。
Operator
Operator
And our next question comes from Kristen Stewart from Barclays.
下一個問題來自Barclays的Kristen Stewart。
Kristen Marie Stewart - Research Analyst
Kristen Marie Stewart - Research Analyst
Congrats on a good quarter. I was wondering if you could just provide us with an update on the Pharmaceutical business and some of the legacy Claris manufacturing, FDA warning letters. How are you feeling about that? And how there may be opportunities to de-risk that?
恭喜本季表現不錯。我想請你們更新一下製藥業務,以及一些Claris既有製造端的FDA警告信進展。你們對此感受如何?以及是否有機會降低相關風險?
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Our Pharmaceutical business is -- our strategy is starting to take shape. It took a little bit. We have built a second-to-none formulation team between India and Northern Illinois, very talented vis-à-vis our partnership to the -- to launch the insulin product, dexmed. And this is just the beginning of a very long pipeline.
我們的製藥業務——我們的策略正開始成形。這花了一點時間。我們在印度與伊利諾伊州北部之間建立了一支首屈一指的配方團隊;就我們與合作夥伴共同推出胰島素產品dexmed而言,團隊非常有才華。而這只是非常長的產品管線的開端。
When it comes to Claris, what we call Baxter Ahmedabad, we are doing everything that we have spoken to the FDA and have told the FDA we're going to do. It's up to the FDA to lift or to inspect us again and provide us with their feedback, okay? But nevertheless, we are de-risking any Claris opportunity for the future by having ultimate supplies for almost everything that we make there. And also for the future molecules, we are de-risking that by going to CMOs instead and having Claris possibly as a backup in the future.
談到Claris,也就是我們所稱的百特艾哈邁達巴德(Baxter Ahmedabad),我們正在做所有我們已與FDA溝通、並告訴FDA我們會做的事情。是否解除、或再次對我們進行稽查並提供回饋,取決於FDA,好嗎?但無論如何,我們正透過為幾乎所有在那裡生產的產品建立替代供應來源,來降低未來任何Claris相關機會的風險。此外,對於未來的分子(產品),我們也透過改由委外製造商(CMO)來降低風險,並讓Claris在未來可能作為備援。
There's one molecule that I want to speak about, the name of the molecule -- but that molecule we're developing in Ahmedabad, but also we're going to have a pilot operation in our Northern Illinois facilities. So we can have possibly a backup. This is more of a longer term. So we're doing not only everything that we told the FDA we're going to do to remediate the warning letter that was given to us the day that we bought the company, but also we are doing everything we can to de-risk any future revenue stream. Now the performance of the business is doing very well. It's double-digit growth. That business is resilient. It's doing well. And it's not only in the U.S., but it's also in Europe, that it's doing well. So this is the state of our Pharmaceutical business.
有一個分子我想談一下,這個分子的名稱——但這個分子我們在艾哈邁達巴德開發,同時也會在我們伊利諾伊州北部的設施進行試點作業。因此我們可能會有一個備援。這比較偏長期。所以我們不僅在做所有我們告訴FDA、為了改善我們在收購公司當天就收到的警告信而要做的補救措施,同時也在盡一切努力降低任何未來營收來源的風險。目前該業務的表現非常好。是雙位數成長。這個業務具韌性。表現良好。而且不僅在美國,在歐洲也同樣表現良好。這就是我們製藥業務的現況。
Kristen Marie Stewart - Research Analyst
Kristen Marie Stewart - Research Analyst
And just as a follow-up, do you still anticipate that you may be able to move beyond the warning letter issue mid next year. I think that's what you said before. And due to some of the actions that you're taking, what will be kind of the P&L impact of that? Could that put a little bit more pressure on the margin side for 2020?
再追問一下,你們是否仍預期可能在明年年中之後走出警告信問題?我記得你們之前是這麼說的。而基於你們正在採取的一些行動,對損益表(P&L)的影響大概會是什麼?這是否會讓2020年的毛利率/利潤率面臨更大壓力?
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
We have done a couple of things. We accelerated the development and pulling some molecules from the future that we think in any case will be able to offset any negatives that will come out of a potential. And I cannot actually rate likely or unlikely because I'm not the FDA. So right now our plans for 2021, if happens, if we get the clearance and can commercialize products that are new on file from the plant, will be great. We'll follow our plan. If that has any postponement for whatever reason, we have backup plans that will probably not alter the trajectory of that business. So there's upside if that happens, if we are successful in 2021.
我們做了幾件事。我們加速開發,並把一些原本在更後期的分子提前,我們認為無論如何,這些都能抵消潛在情況可能帶來的任何負面影響。而我其實無法評估可能性高或低,因為我不是FDA。所以目前我們對2021年的規劃是:如果事情發生、如果我們獲得放行並能將工廠已申報在案的新產品商業化,那會很棒。我們會依照計畫執行。如果因任何原因有所延後,我們也有備援計畫,應該不會改變該業務的發展軌跡。因此,如果我們在2021年成功,這會帶來上行空間。
Operator
Operator
And our final question comes from the line of Matt Taylor from UBS.
我們的最後一個問題來自瑞銀(UBS)的 Matt Taylor。
Matthew Charles Taylor - Equity Research Analyst of Medical Supplies & Devices
Matthew Charles Taylor - Equity Research Analyst of Medical Supplies & Devices
I wanted to follow up on a couple of things in the Renal business. So I guess first, Joe or Jay, you're talking about the investments that you're planning according to the model that could come out. I guess I was wondering if you could share with us some insight into those plans in terms of the scale that you're currently planning for, meaning, if you do invest that $500 million, could you help us understand what number of additional patients or dollars that would allow you to address? And just give us a little bit more of the road map.
我想就腎臟業務的幾件事再追問一下。所以我想先問,Joe 或 Jay,你們在談到依照可能出爐的模型所規劃的投資。我想請問你們是否能就這些計畫提供一些洞見,特別是你們目前規劃的規模;也就是說,如果你們投資那 5 億美元,能否協助我們理解這將讓你們能夠涵蓋多少額外的病患數或對應多少金額的業務?也請再多給我們一點路線圖。
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Matt, you think about this, if you read the executive order, is the significant amount of interpretations and things they have buried in, that's why they have the comment and that's why the rule is not there yet. But think about this today. We are 12% penetrated in PD in the United States. Remember, this is a home -- okay, there's 3 pillars to it, 2 of them are interconnected, which is the transplantation process and number of available kidneys to be transplanted with a lot of incentives not only -- no, in terms of health care, insurance for donors and things like that, all the way to moving from the clinic to the home. Two different modalities, home hemodialysis and PD. Baxter is a leader with close to 70% of market share in PD on a global basis, in U.S. around the same number, okay?
Matt,你想想看,如果你去讀那份行政命令,裡面有大量的解釋空間以及他們埋在其中的內容,這也是為什麼會有徵詢意見期、以及為什麼規則到現在還沒出來。但先看今天的現況。我們在美國的腹膜透析(PD)滲透率是 12%。請記得,這是一個居家——好,這裡有三大支柱,其中兩個是相互連結的:移植流程,以及可供移植的腎臟數量;同時也有很多誘因,不僅——不,是在醫療照護層面,包含捐贈者的保險等各種措施,一直到把治療從診所移到居家。兩種不同的治療模式:居家血液透析與 PD。Baxter 在全球 PD 市場的市占率接近 70%,在美國也差不多是同樣的數字,對吧?
So if it's 12% in U.S. and there is a 50% population that is being target for demonstration. If you look at the targets of the government, it's not inconceivable to think about double patients just in the period of demonstration within the 7 years of the demonstration period. So it tells you that you would double the incident patients, not the prevalent, but the incident patients going forward. That's how we have done some of our analysis. But our plans are flexible. So we can flex up the investment if we need to or flex down the investment because it's progressive. There is Phase I with no investment, Phase II with some investment and Phase III, which is to build a new plant.
所以如果美國是 12%,而且有 50% 的人口被鎖定為示範計畫的目標。如果你看政府的目標,在 7 年的示範期間內,僅在示範期就把病患人數翻倍,並非不可想像。所以這告訴你,未來你會把新發病患(incident patients)翻倍,而不是現有病患(prevalent patients),而是往後的新發病患。這就是我們做部分分析的方式。但我們的計畫是有彈性的。因此我們可以視需要上調投資,或下調投資,因為這是循序漸進的。第一階段不需要投資,第二階段需要一些投資,第三階段則是興建新廠。
All of them we will launch very similarly in time because they have different lead times for execution. But those are designed to support the program as it was designed, but as I said to you, if this rule comes up in November, we will have the ability to adjust our plans. But right now, we want to ensure that the government knows, our investor knows, our patients and customers know that we are committed to the program and we'll do everything possible to help the patients get the therapy that they deserve and for us, as a company, to grow in this sector, which is so important and it has been so underestimated and underpenetrated for so many years, not only in the U.S., but across the globe.
我們會在時間上以非常相近的節奏推進這些項目,因為它們在執行上有不同的前置期。這些設計是為了支援該計畫原本的設計;但如我跟你說的,如果這項規則在 11 月出爐,我們將有能力調整我們的計畫。但現在,我們希望確保政府知道、投資人知道、病患與客戶知道,我們對這個計畫是承諾投入的;我們會盡一切可能協助病患獲得他們應得的治療,同時也讓我們公司在這個領域成長——這個領域非常重要,且多年來不論在美國或全球,都被嚴重低估、滲透率也長期偏低。
Matthew Charles Taylor - Equity Research Analyst of Medical Supplies & Devices
Matthew Charles Taylor - Equity Research Analyst of Medical Supplies & Devices
And if I could just sneak in one follow-up. You mentioned that a lot of the data that you've presented on THERANOVA, and I was wondering if you have any updated thoughts about giving some differential reimbursement for that product?
如果我可以再偷偷追問一個問題。你提到你們在 THERANOVA 上所呈現的許多數據,我想請問你們對於是否能為該產品提供差異化給付(reimbursement),有沒有任何更新的想法?
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Well, we are here waiting for a decision from -- actually not from HHS, but probably from -- between the HHS and the scoring process that happens at the budget office. So we know as much as you do. But we are excited about the possibility. And we have several different avenues to get done over in the U.S. Most importantly, we have agreed with the FDA on the de novo process. And this challenge that we have back in the U.S. will be timely resolved.
嗯,我們正在等待一個決定——其實不是來自美國衛生與公共服務部(HHS),而可能是——介於 HHS 與預算辦公室所進行的評分(scoring)流程之間。所以我們知道的跟你一樣多。但我們對這個可能性很興奮。而且我們在美國有幾條不同的路徑可以推進。最重要的是,我們已與 FDA 就 de novo 流程達成一致。我們在美國面臨的這項挑戰將會及時獲得解決。
And the plant -- one of the issues that we had at the plant, we tried to ramp up the plant too fast because our dialyzers volume went up between 2 different forecasts. And when we tried to do the ramp-up, we encountered some issues because the plant was underutilized at that moment. But with this -- no, not all bad, there's a few things good come out of it. And one of them is that we're going to be fully staffed and equipped on our order lines and our plant in Opelika to be able to have the ability to produce THERANOVA when it's needed.
至於工廠——我們在工廠遇到的一個問題是,我們把產能爬坡拉得太快,因為我們的透析器(dialyzers)需求量在兩種不同的預測之間上升了。當我們嘗試加速爬坡時,遇到了一些問題,因為當時工廠的產能利用率偏低。但就這件事而言——不,並非全是壞事,也有幾件好事因此產生。其中之一是,我們將在訂單產線以及位於 Opelika 的工廠完成滿編與設備到位,以便在需要時具備生產 THERANOVA 的能力。
Operator
Operator
And that concludes our question-and-answer session. Ladies and gentlemen, this concludes today's conference with Baxter International. Thank you all for participating. Everyone, have a great day.
以上為我們的問答環節。各位女士、先生,Baxter International 今日的電話會議到此結束。感謝各位的參與。祝各位有美好的一天。